These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 12445558

  • 1. Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles.
    Wang JX, Sun X, Zhang ZR.
    Eur J Pharm Biopharm; 2002 Nov; 54(3):285-90. PubMed ID: 12445558
    [Abstract] [Full Text] [Related]

  • 2. [Study on brain targeting 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine pharmacosomes].
    Zhang ZR, Wang JX.
    Yao Xue Xue Bao; 2001 Oct; 36(10):771-6. PubMed ID: 12579979
    [Abstract] [Full Text] [Related]

  • 3. [Preparation and liver targeting of floxuridinyl dibutyrate solid lipid nanoparticles].
    Li JJ, Yang GD, Wang HY, Zhang SQ.
    Yao Xue Xue Bao; 2008 Jul; 43(7):761-5. PubMed ID: 18819483
    [Abstract] [Full Text] [Related]

  • 4. [Optimization of the preparation of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine pharmacosomes using central composite design].
    Zhang ZR, Wang JX, Lu J.
    Yao Xue Xue Bao; 2001 Jun; 36(6):456-61. PubMed ID: 12585133
    [Abstract] [Full Text] [Related]

  • 5. In-vitro stability and cytostatic activity of liposomal formulations of 5-fluoro-2'-deoxyuridine and its diacylated derivatives.
    van Borssum Waalkes M, van Galen M, Morselt H, Sternberg B, Scherphof GL.
    Biochim Biophys Acta; 1993 May 14; 1148(1):161-72. PubMed ID: 8499464
    [Abstract] [Full Text] [Related]

  • 6. In vivo distribution and antitumour activity of liposomal 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine.
    Van Borssum Waalkes M, Fichtner I, Dontje B, Lemm M, Becker M, Arndt D, Scherphof GL.
    J Microencapsul; 1992 May 14; 9(3):335-46. PubMed ID: 1403484
    [Abstract] [Full Text] [Related]

  • 7. The antitumour effect of lipophilic derivatives of 5-fluoro-2'-deoxyuridine incorporated into liposomes.
    Supersaxo A, Rubas W, Hartmann HR, Schott H, Hengartner H, Schwendener RA.
    J Microencapsul; 1988 May 14; 5(1):1-11. PubMed ID: 2974073
    [Abstract] [Full Text] [Related]

  • 8. Novel galactosylated SLN for hepatocyte-selective targeting of floxuridinyl diacetate.
    Lian J, Zhang S, Wang J, Fang K, Zhang Y, Hao Y.
    J Drug Target; 2008 Apr 14; 16(3):250-6. PubMed ID: 18365887
    [Abstract] [Full Text] [Related]

  • 9. Efficient intracellular delivery of 5-fluorodeoxyuridine into colon cancer cells by targeted immunoliposomes.
    Koning GA, Kamps JA, Scherphof GL.
    Cancer Detect Prev; 2002 Apr 14; 26(4):299-307. PubMed ID: 12430634
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Characterization of organ-specific immunoliposomes for delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model.
    Mori A, Kennel SJ, van Borssum Waalkes M, Scherphof GL, Huang L.
    Cancer Chemother Pharmacol; 1995 Apr 14; 35(6):447-56. PubMed ID: 7882453
    [Abstract] [Full Text] [Related]

  • 12. Controlled release of 5-fluoro-2'-deoxyuridine by the combination of prodrug and polymer matrix.
    Endoh H, Kawaguchi T, Seki T, Hasegawa T, Juni K.
    Chem Pharm Bull (Tokyo); 1991 Feb 14; 39(2):458-64. PubMed ID: 1829027
    [Abstract] [Full Text] [Related]

  • 13. Lactoferrin bioconjugated solid lipid nanoparticles: a new drug delivery system for potential brain targeting.
    Singh I, Swami R, Pooja D, Jeengar MK, Khan W, Sistla R.
    J Drug Target; 2016 Feb 14; 24(3):212-23. PubMed ID: 26219519
    [Abstract] [Full Text] [Related]

  • 14. Toxicity of liposomal 3'-5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in mice.
    van Borssum Waalkes M, Goris H, Dontje BH, Schwendener RA, Scherphof G, Nijhof W.
    Anticancer Drug Des; 1998 Jun 14; 13(4):291-305. PubMed ID: 9627669
    [Abstract] [Full Text] [Related]

  • 15. Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells.
    Koning GA, Gorter A, Scherphof GL, Kamps JA.
    Br J Cancer; 1999 Aug 14; 80(11):1718-25. PubMed ID: 10468287
    [Abstract] [Full Text] [Related]

  • 16. Enhanced liver targeting by synthesis of N1-stearyl-5-Fu and incorporation into solid lipid nanoparticles.
    Yu BT, Sun X, Zhang ZR.
    Arch Pharm Res; 2003 Dec 14; 26(12):1096-101. PubMed ID: 14723346
    [Abstract] [Full Text] [Related]

  • 17. 5'-O-Palmitoyl- and 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine--novel lipophilic analogues of 5'-fluoro-2'-deoxyuridine: synthesis, incorporation into liposomes and preliminary biological results.
    Schwendener RA, Supersaxo A, Rubas W, Weder HG, Hartmann HR, Schott H, Ziegler A, Hengartner H.
    Biochem Biophys Res Commun; 1985 Jan 31; 126(2):660-6. PubMed ID: 3156589
    [Abstract] [Full Text] [Related]

  • 18. In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery.
    Jose S, Anju SS, Cinu TA, Aleykutty NA, Thomas S, Souto EB.
    Int J Pharm; 2014 Oct 20; 474(1-2):6-13. PubMed ID: 25102112
    [Abstract] [Full Text] [Related]

  • 19. Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration.
    Martins SM, Sarmento B, Nunes C, Lúcio M, Reis S, Ferreira DC.
    Eur J Pharm Biopharm; 2013 Nov 20; 85(3 Pt A):488-502. PubMed ID: 23994244
    [Abstract] [Full Text] [Related]

  • 20. Liposome-incorporated 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine as a slow-release anti-tumor drug depot in rat liver macrophages.
    Van Borssum Waalkes M, Scherphof GL.
    Sel Cancer Ther; 1990 Nov 20; 6(1):15-22. PubMed ID: 2140463
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.